Roche reached an agreement with China-based Rona Therapeutics to secure worldwide rights to an ALK7-targeting RNAi candidate aimed at obesity and metabolic disease. The structure includes up to $100M in upfront and milestone payments, with additional potential development, regulatory, and commercial payments of as much as $1.06B plus royalties. The deal follows a broader pattern of China-to-West licensing that is increasingly focused on cardiometabolic targets beyond traditional small molecules. For Roche, RNAi represents a mechanism-shift for selective modulation of adiposity-related biology. Competitors will watch the candidate’s delivery strategy and pharmacodynamics, since ALK7 biology may require dosing schedules that maximize target knockdown while maintaining tolerability. More broadly, the financing suggests pharma is still willing to pay for platform-adjacent assets with clear mechanisms—even when clinical packages are early—so long as the target and delivery rationale fit established metabolic risk categories.